Poster-Disease-modifying Therapy
October 25, 2021
Safety and Efficacy of Siponimod in Patients with Active Secondary Progressive Multiple Sclerosis Identifying As Hispanic from the Expand Study
Background: In the Phase 3 EXPAND trial siponimod, a selective S1P receptor modulator, significantly reduced risk of 3-month and 6-month...
Poster-Disease-modifying Therapy
October 25, 2021
Characteristics and Outcomes By Employment and Education Status for Patients Treated with Peginterferon Beta-1a or Intramuscular Interferon Beta-1a
Background: Although socioeconomic disparities that lead to differences in multiple sclerosis (MS) outcomes have been identified, specific...
Poster-Disease-modifying Therapy
October 25, 2021
Analyses of the Effect of Baseline Age on the Efficacy and Safety of Siponimod in Patients with Active Secondary Progressive Multiple Sclerosis from the Expand Study
Background: Siponimod is a selective S1P receptor (S1P1 and S1P5) modulator, approved in the USA for treatment of relapsing forms of MS,...
Poster-Disease-modifying Therapy
October 25, 2021
Assessing the Impact of Fingolimod Adherence on Relapse and Costs Using Marginal Structural Models
Background: Disease modifying therapies (DMTs) for relapsing MS are most effective when patients adhere to them as prescribed. Published...
Poster-Disease-modifying Therapy
October 25, 2021
Olikos Study Design: Exploring Maintained Ofatumumab Efficacy in Relapsing MS Patients Who Transition from Intravenous Anti-CD20 Therapy
Background: B-cell depletion in patients with relapsing multiple sclerosis (RMS) using anti-CD20 monoclonal antibodies (mAbs) reduces...